This proposed order, if finalized, will remove oral phenylephrine hydrochloride and oral phenylephrine bitartrate as nasal decongestant active ingredients because they are not effective, FDA stated.
Orlynvah is used to treat uncomplicated urinary tract infections caused by certain microorganisms in adult women who have limited or no alternative oral antibacterial treatment options.